Gamida Cell Ltd. (GMDA) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update
November 15, 2021 7:00 AM ESTNew data being presented at American Society of Hematology (ASH) Annual Meeting demonstrating GDA-201 overall survival rate of 78% at two years with a median duration of response of 16 months and long-term clinical benefit of omidubicel with long-lasting hematopoietic recovery
Finished third quarter of 2021 with $121 million in cash; reassessing expected spending and prior financial guidance due to the revised timing of the omidubicel BLA submission
Company to host conference call at 8:00 a.m. ET today
BOSTON--(BUSINESS... More



